1 / 36

Stakeholder perspectives on the cost of cancer care

Stakeholder perspectives on the cost of cancer care. Neal J. Meropol, M.D. Fox Chase Cancer Center Philadelphia, PA May 30, 2009. Economics of Cancer Care: It’s Everyone’s Problem. Why focus on oncology?. Cancer is life-threatening Cancer is common

aretha-fernandez
Download Presentation

Stakeholder perspectives on the cost of cancer care

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Stakeholder perspectives on the cost of cancer care Neal J. Meropol, M.D. Fox Chase Cancer Center Philadelphia, PA May 30, 2009 Economics of Cancer Care:It’s Everyone’s Problem

  2. Why focus on oncology? • Cancer is life-threatening • Cancer is common • Treatments and diagnostics are increasingly costly • High cost drugs command attention • Treatments have only modest benefit in many circumstances

  3. What the media tells us • “Targeted therapy save lives!” • “We’re going to bankrupt the economy!” • “The pharmaceutical industry is evil!”

  4. What we should be asking • What does this mean for individual patients and their decisions about treatment? • What does this mean for how we invest in, develop, and pay for new cancer treatments?

  5. Patients The Cost of Care Has Wide Impact Payers Employers Producers Providers

  6. What are we spending?

  7. US Health Expenditures and GDP Adapted from C. Borger, et al. Health Affairs 25(2): w61-w73, 2006; Reproduced in Meropol and Schulman, J Clin Oncol, 2007

  8. Growth in healthcare spending is greater than growth in GDP Healthcare Costs: A Primer, Kaiser Family Foundation, 2007

  9. More spending = Better health Meropol and Schulman, J Clin Oncol, 2007

  10. Cancer Survival Worldwide adapted from Coleman et al. Lancet Oncology, 2008 http://www.oecd.org/document/16/0,3343,en_2649_34631_2085200_1_1_1_1,00.html

  11. NIH Estimates for Cancer Costs in the United States: 2007 • Total costs: $219 billion • $89 billion for direct medical costs • US spends ~$2 trillion on healthcare per year American Cancer Society

  12. Oncology Drug Contribution to Spending Growth - 2007 Growth Rate All clinic drug expenditures 9.9% Antineoplastics 16% *Cancer drugs are #1 among hospital and clinic drug expenditures *In general, drugs account for only 10% of healthcare spending Hoffman JM et al. Am J Health-Syst Pharm, 2009

  13. Cost Effectiveness of Colon Cancer Drug Treatment Wong et al. Cancer, 2009

  14. Cost Effectiveness of Adjuvant Therapy for Stage III Colon Cancer British payer perspective • Addition of oxaliplatin to FU/LV (MOSAIC) • £ 2970 per QALY gained • Capecitabine vs. Mayo Clinic FU/LV • £ 3320 savings per patient • Extrapolated: FOLFOX vs. Capecitabine • £ 13,000 per QALY gained Pandor et al. Health Technology Assessment, 2006

  15. Considerations for Innovators(producers)

  16. It costs $1 billion to develop a new drug Adams and Brantner. Health Affairs, 2006

  17. A double-edged sword • Biotechnology/oncology is an attractive realm for investment • Patients benefit from new drugs • However, • Potential for profit-driven inefficiencies in drug development • Incentives for marginally better treatments • Potential disincentive for identification of predictive markers/personalized medicine

  18. Some assumptions about targeted/personalized drug development may not be true • Certainly true • Smaller market - bad • Competitive advantage - good • Uncertain • Drug development will be faster, cheaper, more successful? • Patients will stay on treatment longer? • New markets will be identified? • Pricing premium based on value and novelty will offset narrowed market

  19. The impact on patients

  20. Prospect Theory: People Care More About Loss Than Gain Therefore, cancer patients may place high value on treatments with “modest” benefit Weinfurt, K. P. J Clin Oncol; 25:223-227 2007

  21. Increased financial burden on families • Delay in seeking treatment • Limit/alter treatment Individual patients feel the burden • Insurance premiums • Co-pays • Co-insurance • Tiered formularies • Part D donut hole

  22. The Financial Burden of Cancer • 29% of families spend >10% of income on cancer (Banthin, JAMA, 2006) • KFF/USA Today Survey • Burden of costs on the family – 17% major burden • 25% used up all or most of savings • 13% borrowed from relatives • 11% sought charity • 8% delayed or did not get care because of cost • 22% lower income • 10% spent >%18K out-of-pocket in 2003-04 (Goldman, Health Affairs, 2006)

  23. Cost is a component of decision making for patients Toxicities Benefits Monetary Costs

  24. Patients Feel Ill-Equipped to Consider Costs • How do I ask about costs, about value? • Will I anger my doctor? • How can I predict costs of treatment? • Where can I get information? • How can I discuss this with my family? • How do I access patient assistance plans? • I don’t have the resources to help me navigate this

  25. What is the oncologist’s role, and how do we deal with this patient issue?

  26. Are oncologists to blame for rising costs? • Oncologist income is tied to chemotherapy administration • Aggressive use of drugs, diagnostics, and technologies, sometimes with limited evidence • Lots of chemotherapy in the weeks before death • It’s easy to give drugs; it’s hard to talk about stopping

  27. On the other hand…. • Who creates demand? • Patients, society? • Why focus on oncologists? • Radiation, diagnostic radiology, surgery • Other members of the supply chain certainly seek to maximize profit • Drug and device makers, pharma, insurers

  28. Oncologists Feel Ill-Equipped to Consider Costs • How do I talk about costs, about value? • How can I predict costs of treatment? • Where do I find the time? • How do I balance my dual responsibilities to society and my individual patients? • I don’t have the resources to help me navigate this

  29. The High Cost of Care Can Widen Disparities in Cancer Outcomes

  30. Changes in Health Insurance Premiums, Inflation, and Workers' Earnings, 2000-2007 INSURANCE EARNINGS INFL Ward, E. et al. CA Cancer J Clin 2008;58:9-31.

  31. As healthcare costs rise, employers will: • Reduce benefits • Reduce wages • Become non-competitive

  32. As healthcare costs rise, providers will provide: • Less “off-label” treatment • Less charity care

  33. Health Insurance Coverage Among Individuals Under Age 65 Years, 2006 (in Millions) Ward, E. et al. CA Cancer J Clin 2008;58:9-31.

  34. Colorectal Cancer Stage is Higher Stage Among White AA Private Uninsured/Medicaid Hispanic Ward, E. et al. CA Cancer J Clin 2008;58:9-31.

  35. Colorectal Cancer Survival is Worse Among Uninsured Private Uninsured Medicaid White AA Hispanic Ward, E. et al. CA Cancer J Clin 2008;58:9-31.

  36. Can we afford the cancer care of the future? • % of GDP spent on cancer care is currently small • However • cancer care is an increasing component of healthcare expenditures • Cost is an increasing consideration for patients, and can lead to disparities in care • Personalized medicine may have unintended economic consequences for the cancer enterprise • Policy solutions must integrate various perspectives, and ultimately address the value of specific interventions and distribution of finite resources

More Related